Furtim Therapeutics LLC

Biotech · Defunct

Poly(carboxybetaine) polymer conjugated to L-asparaginase enzyme for pediatric acute lymphoblastic leukemia treatment

Grants
$225K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Development, Optimization and Analysis of Poly (Carboxy Betaine) Bio-conjugates to L-Asparagianse as PEGylation Alternatives$225,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1620REELIN THERAPEUTICS, INC.——
1621DASFANH BIOSCIENCES, LLC——
1622Verdiva Bio——
1623Furtim Therapeutics LLC——
1624NOVALEX THERAPEUTICS, INC.——
1625RADIKAL THERAPEUTICS, INC.——
1626Chan Zuckerberg Biohub——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.